4.4 Article

Novel Fragment-Based QSAR Modeling and Combinatorial Design of Pyrazole-Derived CRK3 Inhibitors as Potent Antileishmanials

期刊

CHEMICAL BIOLOGY & DRUG DESIGN
卷 84, 期 1, 页码 54-62

出版社

WILEY
DOI: 10.1111/cbdd.12290

关键词

combinatorial library; CRK3; GQSAR; Leishmania; leishmaniasis; QSAR

向作者/读者索取更多资源

The CRK3 cyclin-dependent kinase of Leishmania plays an important role in regulating the cell-cycle progression at the G2/M phase checkpoint transition, proliferation, and viability inside the host macrophage. In this study, a novel fragment-based QSAR model has been developed using 22 pyrazole-derived compounds exhibiting inhibitory activity against Leishmanial CRK3. Unlike other QSAR methods, this fragment-based method gives flexibility to study the relationship between molecular fragments of interest and their contribution for the variation in the biological response by evaluating cross-term fragment descriptors. Based on the fragment-based QSAR model, a combinatorial library was generated, and top two compounds were reported after predicting their activity. The QSAR model showed satisfactory statistical parameters for the data set (r2=0.8752, q2=0.6690, F-ratio=30.37, and pred_r2=0.8632) with four descriptors describing the nature of substituent groups and the environment of the substitution site. Evaluation of the model implied that electron-rich substitution at R1 position improves the inhibitory activity, while decline in inhibitory activity was observed in presence of nitrogen at R2 position. The analysis carried out in this study provides a substantial basis for consideration of the designed pyrazole-based leads as potent antileishmanial drugs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells

Vipul Kumar, Jaspreet Kaur Dhanjal, Priyanshu Bhargava, Ashish Kaul, Jia Wang, Huayue Zhang, Sunil C. Kaul, Renu Wadhwa, Durai Sundar

Summary: A study examined the binding potential of natural compounds Withaferin-A, Withanone, and caffeic acid phenethyl ester to the cell surface receptor TMPRSS2 using molecular docking and molecular dynamics simulations. The results showed that Withanone had stronger interactions with TMPRSS2 and was able to induce changes in its allosteric site. Furthermore, Withanone downregulated TMPRSS2 mRNA expression, suggesting its potential dual action in blocking SARS-CoV-2 entry into host cells.

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2022)

Article Biochemistry & Molecular Biology

Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (Mpro) of SARS-CoV-2 and inhibit its activity

Vipul Kumar, Jaspreet Kaur Dhanjal, Sunil C. Kaul, Renu Wadhwa, Durai Sundar

Summary: The study showed that Withanone (Wi-N) and Caffeic Acid Phenethyl Ester (CAPE) can bind to the SARS-CoV-2 M(pro) enzyme with similar efficacy and binding energy to a known protease inhibitor. This suggests that these natural compounds may have the potential to inhibit the functional activity of the virus, offering a possible therapeutic value for managing COVID-19. Further validation in laboratory and clinical tests is warranted.

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2021)

Article Oncology

Identification and Characterization of MortaparibPlus-A Novel Triazole Derivative That Targets Mortalin-p53 Interaction and Inhibits Cancer-Cell Proliferation by Wild-Type p53-Dependent and -Independent Mechanisms

Anissa Nofita Sari, Ahmed Elwakeel, Jaspreet Kaur Dhanjal, Vipul Kumar, Durai Sundar, Sunil C. Kaul, Renu Wadhwa

Summary: The study introduced a novel multimodal small molecule called Mortaparib(Plus) that abrogates mortalin-p53 interaction, reactivates p53's tumor suppression function, and induces growth arrest or apoptosis of cancer cells. The compound also leads to upregulation of p73, inactivation of PARP1 and CARF proteins, and shows potential as a new anticancer drug candidate.

CANCERS (2021)

Correction Biochemistry & Molecular Biology

Accelerated Molecular Dynamics Applied to the Peptaibol Folding Problem (vol 20, 4268, 2019)

Chetna Tyagi, Tamas Marik, Csaba Vagvolgyi, Laszlo Kredics, Ferenc otvos

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Biochemistry & Molecular Biology

COVID19-inhibitory activity of withanolides involves targeting of the host cell surface receptor ACE2: insights from computational and biochemical assays

Rajkumar Singh Kalra, Vipul Kumar, Jaspreet Kaur Dhanjal, Sukant Garg, Xiaoshuai Li, Sunil C. Kaul, Durai Sundar, Renu Wadhwa

Summary: Research shows that withanolides derived from Ashwagandha have potential therapeutic effects against the SARS-CoV-2 virus by inhibiting the ACE2 protein. Among them, stem extracts demonstrate higher inhibitory potency.

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2022)

Article Biochemistry & Molecular Biology

Molecular mechanism of anti-SARS-CoV2 activity of Ashwagandha-derived withanolides

Jaspreet Kaur Dhanjal, Vipul Kumar, Sukant Garg, Chandru Subramani, Shubhra Agarwal, Jia Wang, Huayue Zhang, Ashish Kaul, Rajkumar Singh Kalra, Sunil C. Kaul, Sudhanshu Vrati, Durai Sundar, Renu Wadhwa

Summary: Research has shown that withanolides from Ashwagandha have the potential to inhibit the activity of the cell surface receptor protein TMPRSS2 and the main viral protein Mpro that are crucial for COVID-19 virus entry into host cells and viral replication. This suggests that Ashwagandha may serve as a promising resource for the treatment of COVID-19.

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2021)

Review Geriatrics & Gerontology

COVID-19, Neuropathology, and Aging: SARS-CoV-2 Neurological Infection, Mechanism, and Associated Complications

Rajkumar Singh Kalra, Jaspreet Kaur Dhanjal, Avtar Singh Meena, Vishal C. Kalel, Surya Dahiya, Birbal Singh, Saikat Dewanjee, Ramesh Kandimalla

Summary: The spectrum of health complications caused by the COVID-19 pandemic is diverse and complex, with neurological complications being more common in elderly patients. There is currently a lack of systematic understanding of the neuro-pathophysiology and manifested neurological complications in elderly COVID-19 patients.

FRONTIERS IN AGING NEUROSCIENCE (2021)

Article Oncology

A monoclonal antibody against annexin A2 targets stem and progenitor cell fractions in tumors

Rajkumar S. Kalra, Gaurav S. Soman, Pradeep B. Parab, Avinash M. Mali, Sagar S. Varankar, Rutika R. Naik, Swapnil C. Kamble, Jaspreet K. Dhanjal, Sharmila A. Bapat

Summary: The monoclonal antibody mAb150 targets cancer stem cells, promoting their reentry into the cell cycle and disrupting tumor dormancy, leading to effective tumor targeting.

TRANSLATIONAL ONCOLOGY (2022)

Article Oncology

A Low Dose Combination of Withaferin A and Caffeic Acid Phenethyl Ester Possesses Anti-Metastatic Potential In Vitro: Molecular Targets and Mechanisms

Anissa Nofita Sari, Jaspreet Kaur Dhanjal, Ahmed Elwakeel, Vipul Kumar, Hazna Noor Meidinna, Huayue Zhang, Yoshiyuki Ishida, Keiji Terao, Durai Sundar, Sunil C. Kaul, Renu Wadhwa

Summary: A combination of low doses of Wi-A and CAPE, two natural compounds found in Ashwagandha leaves and propolis, respectively, exhibits potent anti-migratory and anti-angiogenic activities. This combination acts on cell adhesion/tight junction proteins and inhibits Wnt/β-catenin signaling pathways, leading to the downregulation of EMT-signaling proteins. These findings suggest that this combination may be a potential therapeutic option for metastatic and aggressive cancers.

CANCERS (2022)

Review Biochemistry & Molecular Biology

Protein Structure Readouts of Cancer Drivers for Precision Medicine

Jaspreet Kaur Dhanjal, Rajkumar Singh Kalra

Summary: Cancer is a disease caused by perturbed genes, with driver mutations dictating the functional impacts and progression of the disease. Recently, there has been significant attention on identifying driver events from genomic alterations to develop precision cancer therapies. Predicting cancer drivers using genetic signatures and protein structures can provide more clinically relevant evidence than genetic variations alone.

CURRENT PROTEIN & PEPTIDE SCIENCE (2022)

Article Cell Biology

Identification of a new member of Mortaparib class of inhibitors that target mortalin and PARP1

Hazna Noor Meidinna, Seyad Shefrin, Anissa Nofita Sari, Huayue Zhang, Jaspreet Kaur Dhanjal, Sunil C. Kaul, Durai Sundar, Renu Wadhwa

Summary: In this study, a novel compound called Mortaparib(Mild) was characterized for its ability to interact with mortalin, p53, and PARP1. The compound was found to downregulate the expression and functions of mortalin and PARP1, impeding cancer cell proliferation and migration. Mortaparib(Mild) shows potential as a candidate anticancer compound.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)

Editorial Material Genetics & Heredity

Editorial: Genomic alteration landscapes of aging, metabolic disorders, and cancer: Emerging overlaps and clinical importance

Jaspreet Kaur Dhanjal, Rajkumar Singh Kalra, Dhanendra Tomar, Amrendra K. Ajay

FRONTIERS IN GENETICS (2023)

Article Biochemistry & Molecular Biology

Structure-activity correlations for peptaibols obtained from clade Longibrachiatum of Trichoderma: A combined experimental and computational approach

Dora Balazs, Tamas Marik, Andras Szekeres, Csaba Vagvolgyi, Laszlo Kredics, Chetna Tyagi

Summary: This study investigated the production of peptaibols by various Trichoderma strains and their correlation with structure-activity relationships. The results showed that T. longibrachiatum f. bissettii SZMC 12546 exerted the lowest minimum inhibitory concentrations (MIC) against Gram-positive bacteria and also inhibited the plant pathogenic Gram-negative Rhizobium radiobacter. Molecular dynamics simulations revealed that the folding dynamics of Group A peptaibols were more restricted and had well-folded helical conformations, which may contribute to their bioactivity against bacteria.

COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2023)

Article Oncology

Caffeic acid phenethyl ester (CAPE) confers wild type p53 function in p53Y220C mutant: bioinformatics and experimental evidence

Navaneethan Radhakrishnan, Jaspreet Kaur Dhanjal, Anissa Nofita Sari, Yoshiyuki Ishida, Keiji Terao, Sunil C. Kaul, Durai Sundar, Renu Wadhwa

Summary: The study investigated the potential interaction of caffeic acid phenethyl ester (CAPE) with p53(Y220C) and found that it could restore the wild type p53 (p53(wt)) function, suggesting CAPE as a potential natural drug for treating cancers with p53(Y220C) mutations.

DISCOVER ONCOLOGY (2021)

Article Chemistry, Multidisciplinary

Mode of inhibitory binding of epigallocatechin gallate to the ubiquitin-activating enzyme Uba1 via accelerated molecular dynamics

Paras Gaur, Gabriel Fenteany, Chetna Tyagi

Summary: The study showed that the green tea polyphenol EGCG and its analogs inhibit the ubiquitin-activating enzyme Uba1 by binding favorably at two hot spots on the enzyme. The energetics of binding mirror the experimental potency of the compounds for inhibiting Uba1, and a conformational change in the enzyme complex upon binding may explain the inhibitory activity.

RSC ADVANCES (2021)

Article Biochemistry & Molecular Biology

Dihydropyrimidine derivatives as MDM2 inhibitors

Ali Mehri, Karim Mahnam, Hajar Sirous, Mahmoud Aghaei, Leila Rafiei, Mahboubeh Rostami

Summary: One potential approach for tumor therapy is inhibiting the binding between MDM2 and p53 to reactivate p53 in tumor cells. In this study, Monastrol derivatives were designed as MDM2 inhibitors and evaluated for their cytotoxicity on cancer cells. Compound 5d showed the best inhibitory results in silico and in vitro experiments. These findings suggest that Monastrol derivatives have the potential to be candidates for MDM2 inhibition.

CHEMICAL BIOLOGY & DRUG DESIGN (2024)